Nat Rev Cancer. 2025 Jan 20. IF: 72.5
Metabolic interplays between the tumour and the host shape the tumour macroenvironment.
www.nature.com/articles/s41568-024-00786-4
Nat Med. 2025 Jan 20. IF: 58.7
Artificial intelligence in drug development.
www.nature.com/articles/s41591-024-03434-4
Adv Mater. 2025 Jan 19. IF: 27.4
Creating Single Atomic Coordination for Hypoxia-Resistant Pyroptosis Nano-Inducer to Boost Anti-Tumor Immunotherapy.
www.onlinelibrary.wiley.com/doi/10.1002/adma.202414697
Nat Cancer. 2025 Jan 20. IF: 23.5
Refining biomarker design in light of cancer evolution.
www.nature.com/articles/s43018-024-00884-0
Cancer Commun (Lond). 2025 Jan 18. IF: 20.1
Inhibition of mTOR attenuates the initiation and progression of BRCA1-associated mammary tumors.
www.onlinelibrary.wiley.com/doi/10.1002/cac2.12663
Adv Drug Deliv Rev. 2025 Jan 17. IF: 15.2
Intra-tumoral bacteria in breast cancer and intervention strategies.
www.sciencedirect.com/science/article/pii/S0169409X25000018
Nat Commun. 2025 Jan 20;16:860. IF: 14.7
A high-valence bismuth(V) nanoplatform triggers cancer cell death and anti-tumor immune responses with exogenous excitation-free endogenous H2O2- and O2-independent ROS generation.
www.nature.com/articles/s41467-025-56110-7
Cell Death Differ. 2025 Jan 20. IF: 13.7
Epigenetic regulation of HOXA2 expression affects tumor progression and predicts breast cancer patient survival.
www.nature.com/articles/s41418-024-01430-2
Chem Eng J. 2025 Jan 1;503:158143. IF: 13.3
Self-Assembly Nanomedicine Initiating Cancer-Immunity Cycle with Cascade Reactions for Boosted Immunotherapy.
www.sciencedirect.com/science/article/pii/S1385894724096347
Biomaterials. 2025 Jan 18;317:123111. IF: 12.8
Tunable ion-release biodegradable nanoparticles enhanced pyroptosis for tumor immunotherapy.
www.sciencedirect.com/science/article/pii/S0142961225000304
Biomaterials. 2025 Jan 18;317:123107. IF: 12.8
An all-in-one PEGylated NIR-II conjugated polymer for high-resolution blood circulation imaging and photothermal immunotherapy.
www.sciencedirect.com/science/article/pii/S0142961225000262
Biomaterials. 2025 Jan 17;317:123109. IF: 12.8
A carrier-free ultrasound-responsive polyphenol nanonetworks with enhanced sonodynamic-immunotherapy for synergistic therapy of breast cancer.
www.sciencedirect.com/science/article/pii/S0142961225000286
Semin Cancer Biol. 2025 Jan 17. IF: 12.1
The Dual Function of Autophagy in Doxorubicin-induced Cardiotoxicity: Mechanism and Natural products.
www.sciencedirect.com/science/article/pii/S1044579X25000100
Adv Healthc Mater. 2025 Jan 19. IF: 10.0
Computer-Aided Design of Self-Assembled Nanoparticles to Enhance Cancer Chemoimmunotherapy via Dual-Modulation Strategy.
www.onlinelibrary.wiley.com/doi/10.1002/adhm.202404261
Cancer Treat Rev. 2025 Jan 18;133:102885. IF: 9.6
Therapeutic strategies and landscape of metaplastic breast cancer.
www.cancertreatmentreviews.com/article/S0305-7372(25)00007-6/fulltext
J Colloid Interface Sci. 2025 Jan 18;685:38-48. IF: 9.4
Nanoparticles (NPs)-mediated silencing of GSTP1 expression to reverse chemoresistance for effective breast cancer therapy.
www.sciencedirect.com/science/article/pii/S0021979725001225
Cancer Lett. 2025 Jan 17. IF: 9.1
FOXF2 expression triggered by endocrine therapy orchestrates therapeutic resistance through reorganization of chromatin architecture in breast cancer.
www.sciencedirect.com/science/article/pii/S0304383525000278
Cancer Lett. 2025 Jan 16. IF: 9.1
Targeting Dormant Disseminated Tumor Cells and their Permissive Niche by Pro-Resolving Mediators Derived from Resolution-Phase Macrophages.
www.sciencedirect.com/science/article/pii/S0304383525000321
Cell Death Dis. 2025 Jan 20;16:30. IF: 8.1
Targeting estrogen-regulated system xc- promotes ferroptosis and endocrine sensitivity of ER+ breast cancer.
www.nature.com/articles/s41419-025-07354-0
